Pharma companies seek more time to implement revised norms on manufacturing practices
Schedule M of the Drugs and Cosmetics Rules, 1945 prescribes the good manufacturing practices (GMP) for pharmaceutical products, such as a prompt product recall system for products known or suspected to be defective. Pharma lobby groups have written to the health minister, seeking an extension of the December 2024 deadline to December 2026, citing lack of resources and challenges faced by the industry in implementing the revised norms.